As a result, Cobimetinib + Vemurafenib + Atezolizumab became the first three-drug combination group approved by the FDA for patients with BRAF mutation, unresectable or metastatic MM on 30 July 2020. This evidence concerns the gene BRAF and Miyoshi myopathy.